Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: Short-term results in 50 consecutive procedures

Clinical Cardiology

Volumn 26, Issue 6, 2003, Pages 275-279

  Nielsen, Christopher D ^a   Killip, Donna ^a   Spencer III, William H ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alcohol septal ablation; Asymmetric septal hypertrophy; Hypertrophic cardiomyopathy; Myectomy; Outflow tract obstruction; Pacemaker

Indexed keywords

ALCOHOL; CREATINE KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPLETE HEART BLOCK; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEFIBRILLATION; FEMALE; HEART INFARCTION SIZE; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE OUTFLOW TRACT; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; NONSURGICAL SEPTAL REDUCTION THERAPY; PACEMAKER; SEPTUM PELLUCIDUM; TREADMILL; TREATMENT OUTCOME;

EID: 0038546823     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4950260607     Document Type: Article

References (17)

1. Spirito P, Seidman CE, McKenna WJ, Maron BJ: The management of hypertrophic cardiomyopathy. N Engl J Med 1997;338:775-785
2. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE: Hypertrophic cardiomyopathy. N Engl J Med 1987;316:780-789
3. Wigle ED, Rakowski H, Kimball BP, Williams WG: Hypertrophic cardiomyopathy: Clinical spectrum and treatment. Circulation 1995;92:1680-1692
4. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D: Long-term results of dual chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994;90:2731-2742
5. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS: Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999;99(22)2927-2933
6. Linde C, Gandler F, Kappenberger L, Ryden L: Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. Pacing in cardiology (PIC) study group. Am J Cardiol 1999;83:903-907
7. Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Losse B, Schwartzkopff B: Management of symptomatic hypertrophic obstructive cardiomyopathy - long-term results after surgical therapy. Thorac Cardiovasc Surg 1999;47:213-218
8. McCully RB, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK: Extent ofclinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996;94:467-471
9. Sigwart U: Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-214
10. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S: Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998;31(2):252-258
11. Lakkis NM, Nagueh SF, Kleiman NS, Killip D, Zuo-Xiang HE, Verani MS, Roberts R, Spencer WH III: Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998;98:1750-1755
12. Lakkis NM, Sherif SF, Dunn JK, Killip D, Spencer WH III: Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up. J Am Coll Cardiol 2000;36:852-855
13. Faber L, Ziemssen P, Seggewiss H: Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. J Am Soc Echocardiogr 2000;13:1074-1079
14. Runquist LH, Nielsen CD, Killip D, Gazes PC, Spencer WH III: Electrocardiographic changes after alcohol septal ablation therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2002;90:1020-1022
15. Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Zoghbi WA, Quinones MA, Spencer WH III: Changes in left ventricular diastolic function six months after non-surgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 1999;99:344-347
16. Mazur W, Nagueh SF, Lakkis, NM, Middleton KJ, Killip D, Roberts R, Spencer WH III: Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001;103(11):1492-1496
17. Nagueh SF, Stetson SJ, Lakkis NM, Dillip D, Perez-Verdia A, Entman EL, Spencer WH III, Torre-Amione G: Decreased expression of tumor necrosis factor alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. Circulation 2001;103:1844-1850